OTCMKTS:CSLLY

CSL (CSLLY) Stock Forecast, Price & News

$84.89

-0.47 (-0.55%)

(As of 09/20/2023 ET)

Compare

Today's Range: $84.59
▼
$87.30
50-Day Range: $84.48
▼
$91.08
52-Week Range: $83.30
▼
$110.25

Volume: 86,567 shs
Average Volume: 83,948 shs
Market Capitalization: $82.01 billion

P/E Ratio: N/A
Dividend Yield: 1.40%
Price Target: N/A

Profile Analyst Ratings Chart Competitors Financials Headlines SEC Filings Short Interest

CSL MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.00% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 27.13%
From $2.47 to $3.14 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for CSL.

3.0

Short Interest

Percentage of Shares Shorted
0.00% of the outstanding shares of CSL have been sold short.
Short Interest Ratio / Days to Cover
CSL has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in CSL has recently increased by 40.91%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Yield
CSL pays a meaningful dividend of 1.39%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
CSL does not have a long track record of dividend growth.
Dividend Sustainability
Based on earnings estimates, CSL will have a dividend payout ratio of 37.90% next year. This indicates that CSL will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CSLLY.

1.3

News and Social Media Coverage

News Sentiment
CSL has a news sentiment score of -0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for CSL this week, compared to 3 articles on an average week.
MarketBeat Follows
4 people have added CSL to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, CSL insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 0.06% of the stock of CSL is held by institutions.

1.9

Earnings and Valuation

Earnings Growth
Earnings for CSL are expected to grow by 27.13% in the coming year, from $2.47 to $3.14 per share.
Price to Book Value per Share Ratio
CSL has a P/B Ratio of 5.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About CSL (OTCMKTS:CSLLY) Stock

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSLLY Price History

30 days | 90 days | 365 days | Advanced Chart

CSLLY Stock News Headlines

September 15, 2023 | americanbankingnews.com

CSL (OTCMKTS:CSLLY) & Eagle Pharmaceuticals (NASDAQ:EGRX) Head-To-Head Survey

September 3, 2023 | msn.com

ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

September 21, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 28, 2023 | finanznachrichten.de

Vifor International AG (CSL Vifor): Ferinject® granted upgraded recommendations in 2023 ESC heart failure guidelines

August 17, 2023 | finance.yahoo.com

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

August 15, 2023 | startribune.com

Minnesota halts court action against CSL Plasma for discriminating based on gender identity

August 15, 2023 | msn.com

Compliance brings end to state action against CSL Plasma for gender identity discrimination

August 15, 2023 | msn.com

CSL Limited NPATA of $2.38B, revenue of $13.31B

September 21, 2023 | Behind the Markets (Ad)

[BREAKING] New "Living Missile" to Replace Nuclear Missiles

CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!

August 15, 2023 | fool.com.au

Everything you need to know about the supersized CSL dividend

August 14, 2023 | fool.com.au

CSL share price in focus after FY23 profit guidance beat

August 14, 2023 | reuters.com

Biotech firm CSL's full-year profit rises on higher plasma collections

August 14, 2023 | msn.com

Inflation, currency headwinds take toll on CSL's profit

August 14, 2023 | afr.com

CSL profit rebounds on plasma, blockbuster drug sales

August 14, 2023 | wsj.com

CSL Annual Profit Rises 8% at Constant FX

August 3, 2023 | msn.com

CSL (CMXHF) Price Target Decreased by 5.63% to 212.41

August 3, 2023 | markets.businessinsider.com

RBC Capital Sticks to Its Hold Rating for CSL (CMXHF)

August 1, 2023 | fool.com.au

Why did the CSL share price tumble in July?

August 1, 2023 | markets.businessinsider.com

Wilsons Sticks to Their Buy Rating for CSL (CMXHF)

July 27, 2023 | markets.businessinsider.com

Loop Capital Markets Reaffirms Their Buy Rating on Carlisle Companies (CSL)

July 26, 2023 | sports.yahoo.com

2023 BMW M4 CSL video review | Autoblog Garage

July 18, 2023 | markets.businessinsider.com

Jarden Remains a Buy on CSL (CMXHF)

July 14, 2023 | fool.com.au

If I buy $10,000 of CSL shares right now, how much passive income will I receive?

July 3, 2023 | fool.com.au

Why did the CSL share price sink 10% in June?

June 22, 2023 | fool.com.au

Should I quickly snap up CSL shares while they’re trading around the $280 mark?

June 20, 2023 | bizjournals.com

Inside the launch: CSL Behring's $3.5M-per-dose gene therapy Hemgenix given to first hemophilia B patient

June 18, 2023 | markets.businessinsider.com

UBS Remains a Buy on CSL (CMXHF)

See More Headlines

Receive CSLLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CSL and its competitors with MarketBeat's FREE daily newsletter.

CSLLY Company Calendar

Today: 9/21/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:CSLLY
CUSIP: N/A
CIK: 1274152
Web: www.csl.com.au
Phone: (139) 389-1911
Fax: 61-3-9389-1434
Employees: 30,000
Year Founded: 1904

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: $10.56 billion
Price / Sales: 7.77
Cash Flow: $3.02 per share
Price / Cash Flow: 28.15
Book Value: $15.13 per share
Price / Book: 5.61

Miscellaneous

Outstanding Shares: 966,130,000
Free Float: N/A
Market Cap: $82.01 billion
Optionable: Not Optionable
Beta: 0.64

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Dr. Paul F. McKenzie Ph.D. (Age 57)
MD, CEO & Exec. Director
Comp: $2.75M

Ms. Joy Carolyn Linton B.Com. (Age 58)
BComm, GAICD, Grad Dip AFI, Chief Financial Officer
Comp: $2.05M

Mr. Paul R. Perreault B.A. (Age 66)
Strategic Advisor
Comp: $2.89M

Mr. Mark Dehring
Head of Investor Relations

Mr. Gregory Boss B.S. (Age 62)
BS(Hons), J.D., Exec. VP of Legal & Group Gen. Counsel

Christina Hickie
Sr. Mang. of Communications

Ms. Elizabeth Walker B.A. (Age 53)
M.S., Exec. VP & Chief HR Officer

Dr. Karen Etchberger (Age 65)
Exec. VP of Quality & Bus. Services

Ms. Jemimah Brennan
Head of Communications - Asia Pacific

Mr. William Campbell B.S. (Age 63)
Exec. VP & Chief Commercial Officer

Key Competitors

View All Competitors

CSLLY Stock - Frequently Asked Questions

Should I buy or sell CSL stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CSL in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CSLLY shares.
View CSLLY analyst ratings or view top-rated stocks.
How have CSLLY shares performed in 2023?: CSL's stock was trading at $97.54 at the start of the year. Since then, CSLLY stock has decreased by 13.0% and is now trading at $84.89.
View the best growth stocks for 2023 here.
Are investors shorting CSL?: CSL saw a increase in short interest in August. As of August 31st, there was short interest totaling 3,100 shares, an increase of 40.9% from the August 15th total of 2,200 shares. Based on an average daily trading volume, of 140,500 shares, the days-to-cover ratio is currently 0.0 days.
View CSL's Short Interest.
Is CSL a good dividend stock?: CSL (OTCMKTS:CSLLY) pays an annual dividend of $1.19 per share and currently has a dividend yield of 1.39%.
Read our dividend analysis for CSLLY.

What is CSL's stock symbol?: CSL trades on the OTCMKTS under the ticker symbol "CSLLY."
How do I buy shares of CSL?: Shares of CSLLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CSL's stock price today?: One share of CSLLY stock can currently be purchased for approximately $84.89.
How much money does CSL make?: CSL (OTCMKTS:CSLLY) has a market capitalization of $82.01 billion and generates $10.56 billion in revenue each year.
How many employees does CSL have?: The company employs 30,000 workers across the globe.
How can I contact CSL?: CSL's mailing address is 45 Poplar Road, Parkville C3, 3052. The official website for the company is www.csl.com.au. The company can be reached via phone at (139) 389-1911, via email at bernard.ronchi@csl.com, or via fax at 61-3-9389-1434.

This page (OTCMKTS:CSLLY) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial